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Abstract
Background: Reduced physical performance and impaired mobility are common in elderly patients after acute
coronary syndrome (ACS) and they represent independent risk factors for disability, morbidity, hospital readmission
and mortality. Regular physical exercise represents a means for improving functional capacity. Nevertheless, its
clinical benefit has been less investigated in elderly patients in the early phase after ACS. The HULK trial aims to
investigate the clinical benefit of an early, tailored low-cost physical activity intervention in comparison to standard
of care in elderly ACS patients with reduced physical performance.
Design: HULK is an investigator-initiated, prospective multicenter randomized controlled trial (NCT03021044). After
successful management of the ACS acute phase and uneventful first 1 month, elderly (≥70 years) patients showing
reduced physical performance are randomized (1:1 ratio) to either standard of care or physical activity intervention.
Reduced physical performance is defined as a short physical performance battery (SPPB) score of 4–9. The early,
tailored, low-cost physical intervention includes 4 sessions of physical activity with a supervisor and an home-based
program of physical exercise. The chosen primary endpoint is the 6-month SPPB value. Secondary endpoints briefly
include quality of life, on-treatment platelet reactivity, some laboratory data and clinical adverse events. To
demonstrate an increase of at least one SPPB point in the experimental arm, a sample size of 226 patients is
needed.
Conclusions: The HULK study will test the hypothesis that an early, tailored low-cost physical activity intervention
improves physical performance, quality of life, frailty status and outcome in elderly ACS patients with reduced
physical performance.
Trial registration: Clinicaltrials.gov, identifier NCT03021044, first posted January, 13th 2017.
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Background
Many evidences suggest that physical activity is asso-
ciated with benefit in both primary and secondary
cardiovascular prevention [1–3]. It is known that the
incidence of cardiovascular diseases is age-related and
that reduced physical performance and impaired mo-
bility are significantly more frequent in elderly sub-
jects [4]. In these subjects, functional status
represents a primary indicator of health status and
provides useful prognostic information. Low physical
performance is related to higher rates of morbidity,
frailty, disability, hospitalization and mortality and, in
addition, any hospital admission for acute cardiac
events further reduces the overall physical perform-
ance in such patients [2, 5]. As a matter of fact, some
studies have demonstrated that those who benefit
most from physical activity interventions are the
elderly, but only few previous studies have enrolled
patients aged ≥65 years [6, 7]. This is mainly due to
difficulties related to compliance, associated logistic
problems and lack of encouragement from physicians
[8]. Preserving functional capacity and physical per-
formance in elderly people admitted to the hospital
for acute coronary syndrome (ACS) has become more
important given the aging of population. ACS remains
one of the major causes of mortality and morbidity in
Western countries. The mean age of ACS patients
has increased progressively in recent years and, al-
though current interventional and medical treatment
have significantly improved prognosis, the disability
and morbidity burden is still huge.
Accordingly, efforts to improve physical performance
in elderly patients immediately after hospital discharge
for ACS is likely to improve long-term outcomes. It is
plausible that an early, tailored and low-cost physical
activity intervention in this subset of patients could
improve outcomes through the gain of better functional
independence. We designed the pHysical activity inter-
vention for elderly with redUced physicaL performance
after acute coronary syndrome (HULK) study to address
this issue.
Methods
Study population
HULK is a prospective, multicenter, interventional,
randomized study enrolling patients from three Italian
Cardiology units (Azienda Ospedaliera Universitaria di
Ferrara, Ferrara; Ospedale Santa Maria delle Croci,
Ravenna, Ospedale San Giovanni da Saliceto, Piacenza)
and from three outpatient services dedicated to physical
activity intervention (Center of Biomedical Studies Ap-
plied to Sport, Ferrara; Sport Medicine Center, Ravenna;
Sports Medicine Service, Azienda Unità Sanitaria Locale,
Piacenza). These are three cardiology units with exten-
sive experience in terms of ACS management and three
sports medicine centers with consolidated expertise
about physical exercise for cardiopathic patients. A de-
tailed list of inclusion and exclusion criteria is reported
in Table 1. Briefly, we include patients aged 70 years or
older and admitted to the hospital for ACS with
reduced physical performance at time of discharge
(T0), confirmed 30-days post-discharge, during the
inclusion visit (T1). At the inclusion visit, patients are
randomized to the physical activity intervention or to
the standard of care groups. Physical performance is
assessed with the well validated Short Physical
Performance Battery (SPPB) score [9]. Physical per-
formance is considered reduced if SPPB score ranges
between 4 and 9 [9–11]. Cardiorespiratory fitness
(CRF) is evaluated by the 1-km moderate treadmill
walking test (1 k-TWT) [12, 13].
Table 1 Inclusion and exclusion criteria
Inclusion criteria
• Age≥ 70 years
• Hospital admission for acute
coronary syndrome (ACS) and
coronary artery angiography ±
percutaneous coronary intervention
ACS is defined in presence of
the following criteria (the first
mandatory and at least one
between criterion 2 and 3):
1. Chest pain suggestive of
cardiac origin lasting at
least 20 min
2. ECG changes compatibles
with signs of myocardial
ischemia
3. Detection of rise of cardiac
biomarkers
• Informed consent
• SPPB score 4–9 at the
inclusion visit (T1)
Exclusion criteria
• Short portable mental
status questionnaire
(SPMSQ) < 4
SPMSQ is performed as first
test. If it results less than
4 the patient is excluded
• Life expectancy < 12 months
• The patient is not discharged at
home, but he/she is transferred
from the cardiology unit to
other hospital unit or
community structure
• Chronic heart failure NYHA III-IV.
• Left ventricle ejection fraction < 30%.
• Severe aortic or mitral valvulopathy
• Multivessel coronary artery disease
or left main coronary artery disease
candidate to CABG
• Planned staged PCI
• Impossibility to perform physical
activity due to physical impairment
ACS = acute coronary syndrome; CABG = coronary artery bypass graft;
PCI = percutaneous coronary intervention; SPPB = short physical
performance battery
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Clinical management and study flow
From hospital admission and ACS diagnosis, all patients
are managed according to international guidelines and
institutional protocols [14]. Coronary artery angiography
(± subsequent coronary revascularization) is performed
according to current guidelines [14]. The choice of the
management and devices of the coronary revasculariza-
tion is left to the operator. However, the protocol in-
cludes a strong recommendation for complete coronary
revascularization with second generation drug eluting
stent. Quantitative coronary analysis (QCA), syntax
score (SS), residual SS (RSS) and functional SS (FSS) of
the index procedure are then also performed. The de-
tailed methodology for calculating QCA and SS are de-
scribed elsewhere [15–17]. The selection of antiplatelet
agent, angiotensin converting enzyme (ACE) inhibitors,
beta-blockers and statins is left to the treating physician.
The protocol suggests, according to current guidelines, a
preferable dual antiplatelet therapy regimen with aspirin
and ticagrelor (for at least 12 months), up-titration at
the maximal tolerated dose of ACE-inhibitor and lipid
lowering treatment to achieve low density lipoprotein
(LDL) < 70 mg/dl [14]. In addition, all patients undergo
a pre-discharge and 1-year transthoracic echocardio-
grams to collect full images regarding systolic and
diastolic function, valve disease and strain. At the
time of the hospital discharge, the investigators
propose the enrolment in the study and the informed
consent is signed. Blood sampling and a brief com-
prehensive geriatric assessment including SPPB is
administered (Fig. 1). As suggested by guidelines, pa-
tients are invited to follow a heart-healthy life style
(physical activity, low salt and low fat diet, no smok-
ing) in order to prevent recurrence of cardiovascular
events [14]. SPPB score is reassessed at the inclusion
visit, 30 ± 5 days after discharge. Only patients con-
firming a SPPB value between 4 and 9 are random-
ized. Of note, data of screened but not randomized
patients (e.g SPPB value < 4 or > 9 at screening and
inclusion visits) are also collected and their clinical
follow-up is recorded.
Randomization
Randomization is performed at the inclusion visit (T1,
30 ± 5 days after hospital discharge), via a dedicated
website and stratified according the following three vari-
ables: sex, clinical presentation (ST-segment elevation
ACS vs. non ST-segment elevation ACS) and SPPB score
at the inclusion (4–6 vs. 7–9). A dedicated website
assigns a unique treatment code, which dictates the
treatment assignment for the subject. Patients are ran-
domized in a 1:1 ratio to standard of care (control group)
or to an early, tailored, low-cost physical activity
intervention (experimental group). Patients not confirm-
ing an SPPB score 4 to 9 thirty days after discharge are ex-
cluded (Fig. 1).
Control group (standard of care)
At the inclusion visit, the investigator stresses again to
patients and relatives the major issues related to a heart-
healthy life style during a 15-min visit with a study doc-
tor. Specifically, an investigator explains the importance
of aerobic physical activity (30–60 min daily, moderate
intensity, eg. brisk walking, for at least 3 days/week) to
minimize cardiovascular risk [14]. A detailed brochure
explaining the benefits of physical exercise is provided to
all patients (Additional file 1). To objectively assess
leisure time physical activity at home before the follow
up visits, each participant is outfitted with a piezoelectric
uniaxial accelerometer (MyWellness Key, Technogym,
Cesena, Italy) attached at the midline of the right anter-
ior hip; participants are instructed to wear it every time
they perform physical activity for a period of 6 months.
The MyWellness Key is a simple and valid tool to detect
all type of physical activity in free-living settings.
Interventional group (tailored physical activity
intervention)
In addition to standard of care, the experimental group
participates in a program of tailored physical activity.
Immediately after the inclusion visit, participants are
referred to the exercise-based secondary prevention
intervention. During the inclusion visit and during the
following physical activity sessions each patient performs
calisthenics exercises (Additional file 2) and then 1 k-
TWT [12]. This protocol has been demonstrated to be a
valid and simple tool for physical performance assess-
ment, and it has been shown to predict survival and
hospitalization in an outpatient setting [13, 18–21]. A
detailed description of the physical activity intervention
is illustrated in Table 2. Briefly, during each session sub-
jects are instructed to select a pace that they could
maintain for 10 to 20 min at a moderate perceived exer-
cise intensity, (11–13 on the 6–20 Borg scale). Heart rate
is monitored continuously and the rate of perceived
exertion (RPE) is acquired every 2 min, while test’s
difficulty is increasing [12]. After the inclusion visit,
activity sessions are scheduled at 60 ± 10, 90 ± 10 and
120 ± 10 days after discharge. All exercise testing and
training sessions are performed while continuing the
prescribed medications. Participants are instructed to
follow the same RPE goals for the home-based exer-
cise program. As the control group, the MyWellness
Key accelerometer is distributed to each participant in
the interventional group to assess home physical ac-
tivity, as well as to enhance motivation. The ultimate
goal of the intervention is the long-term promotion
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Table 2 Experimental group: physical activity intervention
Inclusion visit (T1) Home-based program Following activity sessions
(60 ± 10, 90 ± 10 and 120 ± 10 days after T0)
Pre-test:
• measure of blood pressure
• positioning RS100 Polar heart rate
monitor to constantly evaluate heart rate
• Calisthenics exercises
• 30 to 60 min of continuous
moderate walking a day, at least 3 to
4 and preferably 7 days a week
• Calisthenics exercisesb
Pre-test:
• Measure of blood pressure
• Positioning RS100 Polar heart rate monitor to
constantly evaluate heart rate.
• Evaluation of data recorded by accelerometer.
• Calisthenics exercisesb
Start: walking on the level at 2.0 km/h Start: walking at an updated intensity estabilished
according to reached results in the previous activity
session
Every 30 s: increases of 0.3 km/h up to reach a
walking speed corresponding to a perceived exertion
of 11–13 on the Borg scale for 1 kma.
Every 30 s: increases of 0.3 km/h up to reach a
walking speed corresponding to a perceived exertion
of 11–13 on the Borg scale for 1 kma.
Post-test:
• Measure of blood pressure.
• Counselling on physical activity and daily activities,
such as gardening, or household work.
• Distribution of home accelerometer
Post-test:
• Measure of blood pressure
• Counselling on physical activity and daily activities,
such as gardening, or household work.
• Distribution of home accelerometer
aSubjects walking at a perceived moderate speed < 3.0 km/h will perform the test over the distance of 500-m. At the end of the test the averaged walking speed
will be calculated
bdetailed description in the Additional file 2
Fig. 1 Flow chart of the study. The figure shows the study flow chart for patients admitted to hospital with acute coronary syndrome diagnosis.
SPPB: short physical performance battery. ACS: acute coronary syndrome
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and maintenance of a physically active lifestyle in
order to improve functional ability and physical
performance.
Study visits and follow-up
After the inclusion visit (T1, 30 ± 5 days after hospital
discharge), patients undergo study visits at 6, 12, 24 and
36 months after discharge. During the study visits any
information regarding clinical status, outcome and
adverse events is collected. Compliance to medical treat-
ment is assessed by interview.
Primary endpoint
Primary endpoint is the SPPB score at the 6-month
study visit. The SPPB is a short battery of tests for lower
limb function [9]. Briefly, the SPPB is composed of three
tests: standing balance, usual walking speed and chair
sit-to-stand. The standing balance test consists in the
ability to maintain the standing position for 10 s with
three different foot position: parallel, semi-tandem and
tandem. Walking speed evaluates the time needed to
progress for 4 linear meters with patient’s usual speed,
assigning a different score according to speed. Finally,
chair sit-to-stand assesses the ability to stand from a
chair 5 consecutive times without using arms. The SPPB
score ranges from 0 (worst performance) to 12 (best per-
formance). It has been known that the test has a strong
and independent ability to predict mortality, morbidity
and hospitalization [10, 11]. Many previous studies in-
vestigating the benefit of physical activity intervention
employed the SPPB score as an endpoint [22–24]. The
test is performed by trained study investigators. To
ensure that patients are able to execute commands, a
rapid evaluation of cognitive impairment is performed
using the Short Portable Mental Status Questionnaire
(SPMSQ) [25]. Of note, the staff performing SPPB score
and other tests at the 6-month visit is different from that
of the inclusion visit and it is blinded regarding treat-
ment (experimental vs. standard care).
Secondary endpoints
Secondary endpoints include several different tests and
the collection of clinical adverse events across the entire
study time.
Handgrip strength (HGT)
The HGT involves the use of a dynamometer to measure
the force of contraction of the flexor muscles of the fin-
gers, of muscles of the wrist and forearm. HGT is associ-
ated with nutrition status of the subject, and with
functional recovery post-surgery [26]. Each patient is
asked to squeeze the dynamometer three different times
and the highest of the three is used to reflect HGT. The
measurement is performed with the patient seated, with
the dominant hand and the elbow flexed 90° [26]. All
study staff is educated regarding correct HGT screening.
In all centers a Jamar hydraulic hand dynamometer
(Patterson Medical, Warrenville, Il, USA) is used. The
results are expressed in Kilograms force.
EuroQol-5D, Quality of life questionnaire
The EuroQol-5D is a simple instrument to evaluate
health status and quality of life [27, 28]. It has been pre-
viously validated in patients with cardiovascular disor-
ders, including participants in rehabilitation programs
[29–32]. The EQ-5D instrument measures health status
in 5 dimensions: mobility, self-care, usual activities,
pain/discomfort, and anxiety/depression. Each dimen-
sion is rated according to the following levels: i) no
problems; ii) some problems; iii) extreme problems. The
questionnaire employs a Visual Analogue Scale (VAS) to
quantify perceived health. There is also an algorithm to
collect all data in a single score [29]. It is administered
during the inclusion visit as a basal value and at 6, 12,
24, 36 months.
Advanced Activity Daily Living (aADL)
Advanced activities of daily living are social and physical
activities that are reduced with aging. These reductions
are considered an index of functional decline that
appears before ADL and IADL loss. These activities
include walking, gardening, hobbies, social and group
activities. Besides, the aADL evaluation is related to
functional capacity and long-term prognosis [33]. The
aADL evaluation is characterized by two simple ques-
tionnaires created by Rosow et al. (evaluation of social
and group activities) and Reuben et alt. (physical activity
frequency) [33, 34]. Data about aADL are collected at
hospital admission in clinical medical notes and then
during follow up visits at 6, 12, 24 and 36 months.
7-Day Physical Activity Recall Questionnaire (PAR)
This questionnaire estimates the individual’s time en-
gaged in physical activity including aerobic, strength,
and flexibility activities for the 7 days prior to the inter-
view. It quantifies duration and intensity of physical
activities. Only physical activities of moderate intensity
and greater are counted. From hours spent in moderate,
hard, and very hard intensity physical activities, total
kilocalories/day can be estimated [35]. This question-
naire is administered in both groups during the inclu-
sion visit to assess baseline levels of physical activity.
These data are also used as a basal value in the interven-
tional group to decide the starting physical activity level
during the first session and then at 6, 12, 24 and
36 months, making up a secondary endpoint.
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Adverse events
All adverse events such as all-cause death, cardiovascular
death, all-cause re-hospitalization and cardiovascular re-
hospitalizations are recorded across the entire follow-up
period. A detailed list of all clinical adverse events col-
lected is reported in Table 3. Of note, all adverse events
will be assessed by an independent, blinded adjudication
committee, according to current consensus documents
[36, 37].
Blood sampling
At hospital discharge and during all follow up visits,
venous blood sample is collected in all patients from
an antecubital vein using a 21-gauge needle. The first
2–4 mL of blood are discarded. The remaining is
used to obtain DNA, plasma, and serum samples
which are stored. In addition, platelet function assays
are performed at all time-points. On-treatment plate-
let reactivity is evaluated with light transmission
aggregometry after stimulus with adenosine diphos-
phate and arachidonic acid [38–42]. Laboratory data
(i.e. LDL-cholesterol levels and glycated haemoglobin
value) are also collected during all follow-up visits.
Data collection and management
In each Cardiology unit study investigators collect all
data regarding baseline characteristics, laboratory data,
medical/interventional treatments and follow-up. All
data are entered into a web-based electronic case report
form. Data management and coordination are performed
by Centro di Epidemiologia Clinica della Scuola di
Medicina at the University of Ferrara (Ferrara, Italy) (see
study organization in the Additional file 3). The study is
initiated and supported by the Cardiovascular Center of
the University of Ferrara. All data are transmitted in an-
onymous form to the coordinator center. A reference
number is assigned to each patient enrolled.
Statistical analysis
Continuous data is tested for normal distribution with
the Kolmogorov-Smirnov test. Normally distributed
values are presented as mean ± SD and are compared by
t test and 2-way ANOVA; otherwise as median value
[interquartile range], and the Mann-Whitney U and
Kruskal-Wallis tests are used. Categorical variables are
summarized in terms of number and percentages and
are compared by using Pearson’s chi-squared or two-
sided Fisher’s exact tests. Survival curves are generated
by the Kaplan- Meier method, and differences are evalu-
ated using the log-rank test. Cox proportional hazard
regression models are run to identify independent
predictors of adverse events. All tests are 2-sided and
the statistical significance is defined as p < 0.05. All ana-
lyses are performed with Stata 13 and with R 3.1.2 by
the staff (EM) of the Center for Clinical Epidemiology of
the School of Medicine at the University of Ferrara
(Ferrara, Italy).
Sample size calculation
Taking into account previous studies and preliminary
findings from the FRASER program [11, 16], we expect
to find in the experimental arm an increase of at least
one point in the 6-month SPPB score, as compared
to standard of care. Assuming a standard deviation of
the SPPB score of 2.5, in order to obtain a statistical
power ≥ 80% (alpha 5%), we would require an overall
sample size of 226 patients.
Trial status
This study is led in accordance with the amended
Declaration of Helsinki. The study protocol has been
approved by the hospitals’ ethics committees prior to
the study beginning (November 2016, study ID 161098).
An approved written informed consent is obtained from
all patients at the time of enrolment. The protocol is
registered on ClinicalTrial.gov with the number:
NCT03021044 (January, 13th 2017). The study started
in January 2017 (January, 16th: first patient enrolled)
and is currently ongoing. The achievement of the sample
size target is planned for March 2018 and the initial
results will be available in October 2018.
Table 3 Study endpoints
6 month
after T0
1, 2 and 3 years
after T0
Primary endpoint
• SPPB score X
Secondary Endpoints
• SPPB score X
• Handgrip test X
• All-cause mortality X
• Cardiovascular mortality X
• All-cause re-hospitalization X
• Cardiovascular re-hospitalization X
• aADL score X X
• PAR Questionnaire X X
• LDL- cholesterol level X
• EQ-5D score X X
• Glycated Haemoglobin (HbA1C) level X X
• On treatment platelet reactivity X X
• Nuisance bleedings X X
aADL = advanced activity daily living; EQ-5D = EuroQol 5D; PAR = 7-day
physical activity recall; SPPB = short physical performance battery
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Discussion
The HULK study is designed to evaluate the benefits of
a tailored physical activity intervention on functional
capacity and physical performance in elderly patients
after ACS. The major strengths of our study are: i) a
population reflecting the real-life scenario; ii) the inclu-
sion of high risk patients enrolled after an acute event;
iii) the evaluation of an early tailored low-cost physical
activity intervention; iv) the multi-parametric assessment
of physical performance and functional capacity.
In a cardiovascular setting, elderly patients have more
complications, more impaired physical function and
higher risk than younger patients; hence interventions
including health education, clinical follow up, prevention
of re-hospitalization and prescription of tailored exercise
are more necessary. These particular patients are usually
understudied and underrepresented in large randomized
trials [7]. In fact, the few prospective studies that have
evaluated the effects of physical training in geriatric pa-
tients have shown significant improvements in func-
tional ability, which is highly relevant for the prevention
of disability, and improving of the quality of life [6, 7]
[43, 44]. The U.S. Medicare population registry shows
that in elderly patients physical training interventions
have positive prognostic effects, with a “dose-response”
relationship, in which the dose corresponds to the num-
ber of sessions of the program performed by patients [2,
5]. Data from the LIFE study provided evidence that
structured physical activity interventions improve the
SPPB score in frail elderly subjects, suggesting that
physical activity interventions might have the potential
to reduce the occurrence of disability [23, 24, 44]. SPPB
is a highly sensitive indicator of global health status
reflecting several underlying physiological impairments
[12]. As shown by a recent meta-analysis, SPPB is also
predictive of all-cause mortality in a dose-response man-
ner [45]. Regarding patients with cardiovascular disease,
Weibel et al. demonstrated that education and counsel-
ing for patients with ACS should occur early after dis-
charge with the aim of promoting compliance to
physical activity programs [46]. Revees et al. in a recent
pilot study observed that in elderly patients admitted for
acute heart failure participating in a physical activity
program, the change of SPPB score was strongly and in-
versely related to all-cause re-hospitalizations [22]. The
HULK study summarizes and extends all these experi-
ences. The attention is focused on elderly frail patients.
The physical activity intervention is begun early after hos-
pital discharge and it provides outpatient tailored physical
activity sessions without prolonging hospitalization. The
direct comparison of the HULK program with standard
cardiac rehabilitation programs was beyond the aim of this
trial. The HULK study reflects the real-life scenario in
which usually elderly coronary patents are not referred to
cardiac rehabilitation programs or show a very low
compliance to this type of secondary prevention. For this
reason, the control arm did not include any kind of super-
vised physical intervention. With this background the
HULK study could offer a feasible alternative for elderly
patients’ improvement in terms of physical performance
and functional capacity. Taking into account these con-
cepts, an important role is played by the home-based
component that allows patients to make tailored physical
activity a habit and maintain their improvement. So the
HULK program could help to overcome the main limita-
tions of the current cardiac rehabilitation, such as the high
number of sessions, high costs, low patients’ compliance
and the lacking long-term maintenance of an active
lifestyle.
Conclusions
The HULK study aims to investigate whether an early,
tailored, low-cost physical activity intervention improves
physical performance, quality of life and delays the onset
of disability in elderly ACS patients with reduced func-
tional capacity.
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